In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B brings in $15mm for SpringLeaf Therapeutics

Executive Summary

SpringLeaf Therapeutics Inc. (formerly Entra Pharmaceuticals; drug-device combination therapies) has raised $15mm through the sale of Series B preferred shares. There were six investors, including new backer GlaxoSmithKline PLC’s SR One--which led and contributes one board member--and returning shareholders Flybridge Capital Partners and North Bridge Partners. The company is developing therapeutics by bringing together new or existing therapies with a self-contained subcutaneous delivery system. SpringLeaf Therapeutics has privately raised about $27mm since it was founded in 2007, including a Series A round in 2008.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies